Non - Pandemic

Charts sum it up quite nicely.
Indeed succinctly shows the thinking behind any advice and the tipping point to it only be advisory under current circumstances.

Ironic that they’ve actually gone further than the EMA considering some of the previous points made.

The new advice in regards to signs to look out for etc I was told almost two weeks ago when I got my jab, the under 30’s with no previous health conditions aren’t being called up yet in great numbers, so fundamentally no changes per today’s announcements.

With more time perhaps the pieces will come together to create a clearer picture.
 
Perhaps but I'm not sure what banning it for under 30s would look like if it's not exactly what they've just done.
With the Moderna vaccine coming on stream they have the flexibility to switch under 30's to that without really impacting the vaccine rollout to young people.
They also have not banned those under 30's that have had the first AZ vaccine from having the second shot - so its not banned.
 
Well for one thing they probably wouldn't still go ahead and give AZ to under 30s who've already had it's first dose...
With the Moderna vaccine coming on stream they have the flexibility to switch under 30's to that without really impacting the vaccine rollout to young people.
They also have not banned those under 30's that have had the first AZ vaccine from having the second shot - so its not banned.
Fair enough but surely this means that the under 30s who will get the AZ jab are the vulnerable (+ healthcare workers), the very people who you'd think were at risk.

That said, JVT pointed out that Moderna hasn't been widely used yet so there's no way of knowing if it's going to have the same issues as AZ.
 
Fair enough but surely this means that the under 30s who will get the AZ jab are the vulnerable (+ healthcare workers), the very people who you'd think were at risk.

That said, JVT pointed out that Moderna hasn't been widely used yet so there's no way of knowing if it's going to have the same issues as AZ.
As you say re JVT comments, the trials of all these vaccines (now and in the past) are always limited in numbers. Opening them up to doses in the millions or even billions is bound to throw up some issues that were not encountered in the trials.
 
As was said until millions of people had been vaccinated with the AZ vaccine these figures probably wouldn’t have showed re blood clot cases.

It was a very good idea to include JVT at this press conference as he explains things in simple terms, against sometimes in answers from the experts can be a bit technical and not so easy for people to understand.

Also it was pointed out we have 9 times less daily cases than France because of our continued vaccine rollout.

Due my second AZ vaccine in 9 days time and will be having it and keep up the 99% of people going for their second dose in the UK.
 
I have not seen any official release on blood cot data related to either Moderna or Pfizer - Not sure if that is because there are no cases, or very limited, it should be noted that they are different types of vaccine compared to AZ.
(Also agree on the point of different types of vaccine)
The other issue is the difference between the Oxford-AstraZeneca and the Pfizer-BioNTech vaccines.
There have been two cases of CVSTs after Pfizer in the UK, out of more than 10 million vaccinated, but these did not have the low platelet levels.
However, there remains uncertainty around how common these clots normally are. Estimates range from two cases per million people every year to nearly 16 in every million in normal times and the coronavirus has been linked to abnormal clotting, which may be making these clots more common.
https://www.bbc.co.uk/news/health-56620646
 
Clots in the U.S.
In the U.S., a Miami physician died following complications of immune thrombocytopenic purpura (ITP) after his first dose of the Pfizer COVID-19 vaccine. ITP is a rare autoimmune condition in which the body generates autoantibodies to its own platelets, resulting in low platelet counts, blood clots, and bleeding if the platelet count drops very low. About 50,000 adults are diagnosed with ITP in the U.S. per year. Risk is increased in young women and people with other autoimmune conditions.

In a case series, James Bussel, MD, and colleagues reviewed 20 reports of thrombocytopenia after receipt of the Pfizer and Moderna COVID-19 vaccines in the U.S. Bussel is professor emeritus of pediatrics at Weill Cornell Medical College in New York City who has published extensively on ITP. His group found that 17 of these patients did not have pre-existing thrombocytopenia. Patients' median age was 41 and 11 were women.

"It is not surprising that 17 possible de novo cases would be detected among the well over 20 million people who have received at least one dose of these two vaccines in the United States as of February 2, 2021," they wrote in the American Journal of Hematology. "The incidence of an immune‐mediated thrombocytopenia post SARS‐CoV‐2 vaccination appears either less than or roughly comparable to what would be seen if the cases were coincidental following vaccination, perhaps enhanced somewhat by heightened surveillance of symptomatic patients."

However, they note that "all but one" of these cases occurred after the first dose of the Pfizer or Moderna vaccine.

"One would assume that if the vaccination was unrelated to development of ITP, case occurrences would divide more evenly between the two doses," they write. "...[W]e cannot exclude the possibility that the Pfizer and Moderna vaccines have the potential to trigger de novo ITP (including clinically undiagnosed cases), albeit very rarely."

https://www.medpagetoday.com/special-reports/exclusives/91813
 
Since the Johnson & Johnson ( Janssen ) vaccine passed efficacy it has always been the NHS intention to administer it to the under 30's. The fact that it is a one shot vaccine makes it more likely that the uptake in the lower age groups will be higher.
 
Since the Johnson & Johnson ( Janssen ) vaccine passed efficacy it has always been the NHS intention to administer it to the under 30's. The fact that it is a one shot vaccine makes it more likely that the uptake in the lower age groups will be higher.
Also gets the vaccination programme completed more quickly - no wait for the 2nd dose.